In this episode of "The Top Line," Fierce's Fraiser Kansteiner engages in a conversation with Alexander Scott, senior vice president of integrity at Eisai, to discuss the full approval of Leqembi and what it means for Eisai and, most importantly, for Alzheimer's patients.

To learn more about the topics in this episode: 

• With full Alzheimer's approval in hand, Eisai and Biogen kick off Leqembi's launch in earnest
• After winning full FDA nod for Leqembi, Eisai touts 'promising' study on subcutaneous version
• Eisai, Biogen's Leqembi may face rollout hurdles now, but experts still like the Alzheimer's drug
• Eisai launches 'digital business' Theoria to build out a dementia ecosystem for patients